Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1 […]
BridgeBio Pharma (BBIO) announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The United States Food and Drug Administration has cleared the investigational new drug application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule.
PALO ALTO, Calif., Jan. 03, 2024 BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management.